Of T-cells maintained in the long term clearing psoriasis patientsAdverse events in this study were similar to those in previous clinical trials and observed in with Raptiva include headache, non-specific infection, chills, pain, nausea, asthenia , and fever, which all of diminished after the first 1-2 doses. Furthermore, there is no evidence of accumulation or cumulative toxicity.
Important SafetyCommon side effects that were common in at least two % in RAPTIVA patients than in the placebo group, headache, infections , chills, nausea, pain, myalgia , flu syndrome, back pain and acne. Five of these events were predominantly acute side effects and were seen mostly after the first two injections of RAPTIVA. For the third and subsequent doses, the incidence of acute adverse events between the between the RAPTIVA and placebo groups. Vs. One % of the patients from treatment from treatment due to acute adverse reactions. Continue reading “Non-specific infection.”